新闻
Cordlife: Records FY2024 Revenue Of S$27.8 Million, Fully Resumed Singapore Operations Since 14 January 2025.
03 Mar 2025 11:22FY2024 revenue declined 50.0% to S$27.8 million from S$55.7 million a year ago, mainly due to almost nine months of suspension of the Group's operations in Singapore. Net loss of S$18.7 million in FY2024 (FY2023: Net Profit of S$3.6 million), excluding the impact of the Refund/Waiver for High-Risk tanks, net loss would have been S$8.3 million in FY2024. On 14 January 2025, Cordlife Singapore's Healthcare Services Act License to fully resume operations in Singapore after it was issued with the cord blood banking and human tissue banking licences and are valid for a period of 1 year. Expects FY2025 performance to improve compared to FY2024 on resumption of full operations in Singapore, but the uncertainty of potential claims against the Company could adversely impact the Company's financial performance...
More information available here.
Source: ShareInvestor Express
